Latest Conference Articles

May 14th 2022, 7:37pm

American Urological Association Annual Meeting

Darolutamide was found to have a favorable safety and tolerability profile in patients with metastatic castration-resistant prostate cancer who were enrolled to the phase 1 ARAFOR study and received extended treatment with the agent for more than 4 years.

May 14th 2022, 7:22pm

American Urological Association Annual Meeting

Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

May 14th 2022, 6:55pm

American Urological Association Annual Meeting

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

May 14th 2022, 6:51pm

American Urological Association Annual Meeting

The addition of niraparib to abiraterone acetate and prednisone achieved for promising response rates in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.

May 14th 2022, 6:44pm

American Urological Association Annual Meeting

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

May 13th 2022, 10:02pm

American Urological Association Annual Meeting

PET/CT scans conducted with 18F-rhPSMA-7.3 frequently resulted in post-scan disease upstaging compared with baseline conventional imaging in patients with prostate cancer recurrence.

May 13th 2022, 9:56pm

American Urological Association Annual Meeting

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

May 13th 2022, 9:07pm

American Urological Association Annual Meeting

The addition of the IL15RaFc superagonist N-803 to Bacillus Calmette–Guérin led to prolonged complete responses and disease-free survival (DFS) in patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ and papillary histology, respectively.

May 13th 2022, 9:05pm

American Urological Association Annual Meeting

Patients with metastatic urothelial carcinoma who received pembrolizumab achieved prolonged median progression-free and overall survival after experiencing an immune-related adverse effect.

May 11th 2022, 4:00pm

ESMO Breast Cancer Virtual Meeting

Entrectinib produced deep and durable responses in patients with breast cancer harboring NTRK fusions.

May 10th 2022, 1:17pm

ESMO Breast Cancer Virtual Meeting

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

May 9th 2022, 7:25pm

ESMO Breast Cancer Virtual Meeting

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

May 8th 2022, 10:00am

HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.

May 7th 2022, 10:00am

Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.

May 6th 2022, 11:20pm

The addition of adjuvant abemaciclib to endocrine therapy resulted in a clinically meaningful reduction in the risk of developing invasive disease, particularly incurable distant metastatic disease, in patients with high-risk, hormone receptor–positive, HER2-negative, early breast cancer who comprised cohort 1 of the phase 3 monarchE trial.

May 6th 2022, 9:30pm

The addition of pembrolizumab to chemotherapy led to significant survival benefits without substantial deterioration in health-related quality of life among patients with treatment-naïve, PD-L1–positive advanced triple-negative breast cancer according to results from the phase 3 KEYNOTE-355 trial.

May 6th 2022, 7:35pm

Nearly all patients with HER2-positive breast cancer with brain metastases who received fam-trastuzumab deruxtecan-nxki elicited benefit, according to data from a primary outcome analysis of the phase 2 TUXEDO-1 trial.

May 6th 2022, 7:09pm

ESMO Breast Cancer Virtual Meeting

The combination of alpelisib plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor–positive, HER2-negative advanced breast cancer with PIK3CA mutations.

May 6th 2022, 4:00pm

Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.

May 5th 2022, 7:00pm

Sacituzumab govitecan-hziy maintained clinical benefit in patients with metastatic triple-negative breast cancer regardless of HER2 expression according to a post hoc analysis of the phase 3 ASCENT trial.